Merck & Co., Inc. (MRK.PA)
Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
À la clôture : 05:11PM CET
| Clôture précédente | 98,40 |
| Ouverture | 93,70 |
| Offre | S.O. x S.O. |
| Vente | S.O. x S.O. |
| Var. jour | 93,70 - 99,00 |
| Sur 52 semaines | 64,50 - 109,00 |
| Volume | |
| Volume moyen | 428 |
| Cap. boursière | 251,005B |
| Bêta (mensuel sur 5 ans) | 0,37 |
| Rapport P/E (sur 12 mois) | 18,61 |
| BPA (sur 12 mois) | S.O. |
| Date de bénéfices | S.O. |
| Dividende et rendement à terme | 2,69 (2,73 %) |
| Date ex-dividende | 14 mars 2023 |
| Objectif sur 1 an | S.O. |
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
- ACCESSWIRE
Our Partnerships Help Make Vaccines Accessible Worldwide
Providing vaccines to some of the hardest-to-reach places around the world
© 2023 Yahoo. Tous droits réservés.
